Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Novo Nordisk launches Wegovy in India, a once-weekly weight-loss injection shown to aid obesity treatment and reduce heart ...

A new study analyzing NFHS-5 data reveals India’s most obese state. With alarming obesity rates across cities, experts warn ...

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk is making a strategic move into one of the world's fastest-growing obesity markets by launching its blockbuster ...

A recent study reveals that nearly 20% of Indian households have all adults classified as overweight, while 10% are obese.

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

Heart disease is increasingly impacting young Indian adults, with risks rising silently from age 40. Early screening and ...

CHENNAI: Danish drugs and insulin maker Novo Nordisk launched Wegovy, its latest and the much-awaited weight-loss drug -- a once‑a‑week semaglutide injection, i ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...